Long-acting Injectable Antipsychotics in First-episode Schizophrenia.
- Author:
Hyun Ghang JEONG
1
;
Moon Soo LEE
Author Information
1. Department of Psychiatry, Korea University Guro Hospital, Seoul, Korea. npboard@korea.ac.kr
- Publication Type:Controlled Clinical Trial ; Review
- Keywords:
Antipsychotic agents;
Injections;
Schizophrenia;
Delayed-action preparations
- MeSH:
Antipsychotic Agents;
Delayed-Action Preparations;
Humans;
Recurrence;
Schizophrenia
- From:Clinical Psychopharmacology and Neuroscience
2013;11(1):1-6
- CountryRepublic of Korea
- Language:English
-
Abstract:
Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.
